Mechanism of c-MET in Non-small Cell Lung Cancer and Its Treatment and Testing

Chinese Journal of Lung Cancer

卷:18

Hongge LIANG¹  Mengzhao WANG¹ 

[1] Chinese Academy of Medical Sciences, Chinese Peking Union Medical College, Peking Union Medical College Hospital, 
Beijing 100730, China;

关键词: Lung neoplasms;    c-MET;    HGF;    Treatment;    Testing;   

DOI  :  10.3779/j.issn.1009-3419.2015.12.06

来源: DOAJ

【 摘 要 】

Hepatocyte growth factor/c-MET (HGF/c-MET) signaling pathway can be abnormal activated by many mechanisms such as c-MET mutation, amplification and the overexpression of HGF, and it plays an important role in the development of non-small cell lung cancer (NSCLC), as well as in the tolerance of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in NSCLC. Therefore, c-MET is a new molecular target for the therapy of NSCLC since EGFR and ALK. At present, although the c-MET inhibitors have shown a potential prospect in some clinical trials, its assessment of safety and effectiveness in clinical applications, and the choice of testing methods and standards still need a further discussion. In this paper, we summarized the mechanism of c-MET in NSCLC, as well as its treatment prospect and selection of testing methods.

【 授权许可】

Unknown